3月25日，医脉通（02192）股价表现强劲，盘中大涨7.99%，引发市场关注。截至发稿时，该股报13.9港元，涨幅为6.76%，成交额达8258.83万港元。
医脉通股价大涨主要受其发布的2024年度业绩报告推动。公司公布的财报显示，2024年收益约5.58亿元，同比增长35.5%；毛利约3.27亿元，同比增长30.2%；母公司拥有人应占溢利约3.15亿元，同比增长30.1%。每股基本盈利为43.23分，公司拟派末期股息每股0.1366元，高于上年同期的0.1248元。
值得注意的是，医脉通的精准营销解决方案业务表现突出。2024年，该业务板块收入达5.125亿元，较2023年的3.727亿元增长37.5%。德邦证券最近的研报指出，医脉通正在通过横向拓展和纵向延伸战略布局，不断扩大公司的业务范围和价值链。公司围绕临床专科进行专科化建设与运营，同时在药品临床研究、数字营销和患者管理等方面进行能力建设和投资并购，旨在全面满足制药企业客户的需求。此外，医脉通还计划基于其海量数据开发垂直大模型，进一步增强公司的竞争优势。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.